Expanding role of bisphosphonates in the management of early breast cancer

References

• Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med.360(7), 679–691 (2009).
   PubMed Web of Science ®Google Scholar
• Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J. Clin. Oncol.15(3), 955–962 (1997).
   PubMed Web of Science ®Google Scholar
• Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J. Clin. Oncol.15(4), 1341–1347 (1997).
   PubMed Web of Science ®Google Scholar
• Shapiro CL,Halabi S, Gibson G. Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): first results from CALGB trial 79809. J. Clin. Oncol.26(Suppl. 20), (2008) (Abstract 512).
   Google Scholar
• Brufsky A, Bundred N, Coleman R et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist13(5), 503–514 (2008).
   PubMed Web of Science ®Google Scholar
• Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet359(9321), 1929–1936 (2002).
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol.9(9), 840–849 (2008).
   PubMed Web of Science ®Google Scholar
• Ripamonti CI, Maniezzo M, Campa T et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumor patients with bone metastases treated with bisphosphonates: the experience of the national cancer institute of Milan. Ann. Oncol.20(1), 137–145 (2009).
   PubMed Web of Science ®Google Scholar
• Coleman RE. Bisphosphonates: clinical experience. Oncologist9(Suppl. 4), 14–27 (2004).
   PubMed Web of Science ®Google Scholar
• Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res.15(1), 57–62 (2005).
   PubMed Web of Science ®Google Scholar
• Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem. Biophys. Res. Commun.328(3), 679–687 (2005).
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Avvisati G et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin. Cancer Res.8(5), 1080–1084 (2002).
   PubMed Web of Science ®Google Scholar
• Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br. J. Cancer84(8), 1126–1134 (2001).
   PubMed Web of Science ®Google Scholar
• Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br. J. Cancer96(12), 1796–1801 (2007).
   PubMed Web of Science ®Google Scholar
• Kristensen B, Ejlertsen B, Mouridsen HT et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol.47(4), 740–746 (2008).
   PubMed Web of Science ®Google Scholar
• Daubine F, Le Gall C, Gasser J, Green J, Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J. Natl Cancer Inst.99(4), 322–330 (2007).
   PubMed Web of Science ®Google Scholar
• Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J. Natl Cancer Inst.100(16), 1167–1178 (2008).
   PubMed Web of Science ®Google Scholar
• Burkinshaw R, Thorpe H, Pollard S et al. The AZURE trial-does adjuvant zoledronic acid reduce recurrence in patients with high-risk localized breast cancer? Bone38(Suppl. 1), 70–71 (2006).
   Google Scholar
• Winter MC, Thorpe HC, Burkinshaw R, Beevers SJ, Coleman RE. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response exploratory evidence for direct anti-tumor activity in breast cancer. In: San Antonio Breast Cancer Symposium. (Eds). San Antonio, (2008) (Abstract 5101).
   Google Scholar
• Thurlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med.353(26), 2747–2757 (2005).
   PubMed Web of Science ®Google Scholar
• Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet365(9453), 60–62 (2005).
   PubMed Web of Science ®Google Scholar